EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis‐Associated Hepatocellular Carcinoma by Modulating Tumor‐Associated Macrophages

Yuyang Du, Shasha Wu, Shaoyan Xi, Wei Xu, Liangzhan Sun, Jingsong Yan, Han Gao, Yanchen Wang, Jingyi Zheng, Fenfen Wang, Hui Yang, Dan Xie und 4 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202404756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yuyang Du und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, 518055, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatic Stellate Cells, Tumor-Associated Macrophages, Liver Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) often occurs in the context of fibrosis or cirrhosis. Methylation of histone is an important epigenetic mechanism, but it is unclear whether histone methyltransferases are potent targets for fibrosis‐associated HCC therapy. ASH1L, an H3K4 methyltransferase, is found at higher levels in activated hepatic stellate cells (HSCs) and hepatoma cells. To determine the role of ASH1L in vivo, transgenic mice with conditional Ash1l depletion in the hepatocyte cell lineage ( Ash1l flox/flox Alb cre ) or HSCs ( Ash1l flox/flox GFAP creERT2 ) are generated, and these mice are challenged in a diethylnitrosamine (DEN)/carbon tetrachloride (CCl 4 )‐induced model of liver fibrosis and HCC. Depleting Ash1l in both hepatocytes and HSCs mitigates hepatic fibrosis and HCC development. Multicolor flow cytometry, bulk, and single‐cell transcriptomic sequencing reveal that ASH1L creates an immunosuppressive microenvironment. Mechanically, ASH1L‐mediated H3K4me3 modification increases the expression of CCL2 and CSF1, which recruites and polarizes M2‐like pro‐tumorigenic macrophages. The M2‐like macrophages further enhance tumor cell proliferation and suppress CD8 + T cell activation. AS‐99, a small molecule inhibitor of ASH1L, demonstrates similar anti‐fibrosis and tumor‐suppressive effects. Of pathophysiological significance, the increased expression levels of mesenchymal ASH1L and M2 marker CD68 are associated with poor prognosis of HCC. The findings reveal ASH1L as a potential small‐molecule therapeutic target against fibrosis‐related HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatic Stellate CellsTumor-Associated MacrophagesLiver NeoplasmsLiver CirrhosisMice, TransgenicDisease Models, AnimalAnimalsMiceHistone-Lysine N-MethyltransferaseHumansDiethylnitrosamine

Stichwörter der Autor:innen

ASH1Lfibrosishepatic stellate cells (HSCs)hepatocellular carcinoma (HCC)macrophage

Substanzen

Histone-Lysine N-MethyltransferaseDiethylnitrosamine

Autor:innen und Institutionen

  • Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, 518055, China.
  • Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510275, China.
  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, China.
  • Department of Clinical Oncology, The University of Hong Kong, Hong Kong, 999077, China.
  • Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, 518067, China.
  • Shenzhen Hospital, Southern Medical University, Shenzhen, 518000, China.

ORCID-Profile: Yan Li

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Du, Y., Wu, S., Xi, S., Xu, W., Sun, L., Yan, J., Gao, H., Wang, Y., Zheng, J., Wang, F., Yang, H., Xie, D., Chen, X., Ou, X., Guan, X. Y., & Li, Y. (2024). ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis‐Associated Hepatocellular Carcinoma by Modulating Tumor‐Associated Macrophages. Advanced Science. https://doi.org/10.1002/advs.202404756

Vancouver

Du Y, Wu S, Xi S, Xu W, Sun L, Yan J, et al. ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis‐Associated Hepatocellular Carcinoma by Modulating Tumor‐Associated Macrophages. Advanced Science. 2024. doi:10.1002/advs.202404756

BibTeX
@article{Du2024,
  author = {Du, Yuyang and Wu, Shasha and Xi, Shaoyan and Xu, Wei and Sun, Liangzhan and Yan, Jingsong and Gao, Han and Wang, Yanchen and Zheng, Jingyi and Wang, Fenfen and Yang, Hui and Xie, Dan and Chen, Xi and Ou, Xijun and Guan, Xin-Yuan and Li, Yan},
  title = {ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis‐Associated Hepatocellular Carcinoma by Modulating Tumor‐Associated Macrophages},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202404756}
}
Kostenlos starten →